Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...

US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

The S&P 500 Index ($SPX) (SPY) today is down -1.60%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.35%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.77%. September E-mini S&P futures ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

The S&P 500 Index ($SPX) (SPY) today is down -1.70%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.48%, and the ...

Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

To align with global demand and the company's planned maintenance, LYB expects third quarter operating rates of 85% for North ...

During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...